FOLFIRI + Bevacizumab Administration Order
Bevacizumab should be administered FIRST, before the FOLFIRI chemotherapy components, on Day 1 of each cycle.
Standard Administration Sequence
The correct order of administration for FOLFIRI + bevacizumab is:
- Bevacizumab 5 mg/kg IV - administered first on Day 1
- Irinotecan 180 mg/m² IV - given after bevacizumab on Day 1
- Leucovorin 400 mg/m² IV - administered on Day 1
- 5-FU 400 mg/m² IV bolus - given on Day 1
- 5-FU 2400 mg/m² continuous infusion - over 46-48 hours starting Day 1
This sequence is repeated every 2 weeks 1, 2, 1.
Rationale for Bevacizumab First
Multiple international guidelines consistently specify bevacizumab administration on "day 1" of the FOLFIRI regimen 1, 2, 1, 3. The FDA label for bevacizumab explicitly states it was administered "prior to FOLFOX4 on Day 1" in the E3200 trial, establishing the precedent for anti-VEGF therapy preceding chemotherapy 4.
Practical Administration Details
- Bevacizumab infusion time: First dose over 90 minutes; if tolerated, subsequent doses can be given over 60 minutes, and eventually over 30 minutes 4
- Timing: Bevacizumab is given before starting the irinotecan infusion on the same day
- Cycle frequency: Every 14 days (2-week cycles)
- Duration: Continue until disease progression or unacceptable toxicity 1, 5
Common Pitfalls to Avoid
Do not reverse the order - giving chemotherapy before bevacizumab contradicts established protocols and may theoretically affect the anti-angiogenic mechanism of action. The anti-VEGF effect is intended to "normalize" tumor vasculature before cytotoxic agents are delivered.
Do not split bevacizumab across multiple days - it must be given as a single infusion on Day 1, not divided between days.
Monitor for infusion reactions during the first bevacizumab administration, as this is when hypersensitivity reactions are most likely to occur 4.
This administration sequence has been validated across multiple phase III trials including WJOG4407G, CRYSTAL, and others, demonstrating both efficacy and safety when bevacizumab precedes FOLFIRI chemotherapy 1.